Comparing the effects of ketamine with midazolam on suicidal ideation in suicide attempters

A comparative study of the effects of ketamine with midazolam on reducing suicidal ideation in suicide attempters undergoing intubation treatment

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211121053132N3

Enrollment

Registered

2025-08-11

Start date

2025-07-12

Completion date

Unknown

Last updated

2025-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Suicidal thoughts. Other symptoms and signs involving emotional state

Interventions

Intervention 1: Intervention group: Intubated suicide attempters will receive intravenous racemic ketamine hydrochloride from Exir Company at a dose of 0.5 mg/kg in 100 cc of normal saline, infused ov

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: All patients between 18 to 65 years, who were admitted to the intensive care unit of Khorshid Hospital due to suicide Consent from the guardian or legal supervisor

Exclusion criteria

Exclusion criteria: ECG with extensive abnormal changes History of ketamine abuse or dependence

Design outcomes

Primary

Measure	Time frame
Suicidal ideation score on the Beck-21 Suicidal Ideation Questionnaire scale. Timepoint: After patients are fully conscious (about 24 to 48 hours after receiving the medication). Method of measurement: Beck-21 Suicidal Ideation Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAzade Erfan

Esfahan University of Medical Sciences

Azade.erfan@gmail.com+98 31 3222 2475

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026